AMANDA MURPHY
Associate Director, Investor Relations & Public Relations, Aegerion Pharmaceuticals
Email: amanda.murphy@aegerion.com
Phone: 857-242-5024
Open-label study in patients with partial lipodystrophy-associated NASH featured in oral presentation
Vancouver, British Columbia, March 31, 2017 – Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effective immediately. Dr. Corrigan will serve as a member of the compliance committee.
